Abaloparatide in the treatment of osteoporosis after menopause

Abaloparatide is a synthetic peptide analogue of parathyroid hormone-related protein (PTHrP), is used to manage and treat osteoporosis (1):

• can be combined or administered before antiresorptive therapies such as bisphosphonates to maximize effects
• is not recommended in pediatric patients with open epiphyses or genetic predispositions to bone malignancies

NICE states (2):

• abaloparatide is recommended as an option for treating osteoporosis after menopause in women, trans men and non-binary people, only if they have a very high risk of fracture
• the NICE committee noted "...Clinical trial evidence shows that abaloparatide followed by alendronic acid is more effective at reducing the risk of some types of fracture than placebo followed by alendronic acid. Indirect comparisons suggest that abaloparatide is likely to work at least as well as romosozumab and teriparatide..."

Reference:

1. Akel M, Patel P, Parmar M. Abaloparatide. [Updated 2024 Jan 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
2. NICE (August 2024). Abaloparatide for treating osteoporosis after menopause